Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BridGene FNTB inhibitor
- Development stage
- Preclinical
- Lead developer
- BridGene Biosciences
- Modality
- Small Molecules
01
Overview
BridGene FNTB inhibitor is a preclinical-stage covalent small molecule designed to inhibit the farnesyltransferase beta subunit (FNTB). Developed by BridGene Biosciences using its proprietary IMTAC™ (Isobaric Mass Tagged Affinity Characterization) chemoproteomics platform, the drug is specifically intended for the treatment of solid tumors harboring HRAS mutations. The mechanism of action involves covalently binding to FNTB to block the post-translational farnesylation of the HRAS protein. Farnesylation is a critical modification required for HRAS to localize to the cell membrane and activate downstream oncogenic signaling pathways. By preventing this modification, the inhibitor effectively suppresses HRAS-driven tumor growth. The program is currently in the lead optimization phase.
- Other names
- Covalent FNTB inhibitorBridGene Biosciences FNTB inhibitor
02
Targets
FNTB (Farnesyltransferase beta subunit)
Beyond the preview
Go deeper on BridGene FNTB inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BridGene FNTB inhibitor.